目的 探討復(fù)方苦參腸炎康片聯(lián)合柳氮磺吡啶治療潰瘍性結(jié)腸炎的臨床效果。方法 選取2019年3月—2021年7月亳州市人民醫(yī)院收治的118例潰瘍性結(jié)腸炎患者，隨機分成對照組和治療組，每組各59例。對照組口服柳氮磺吡啶腸溶片，4片/次，3次/d。在對照組基礎(chǔ)上，治療組口服復(fù)方苦參腸炎康片，4片/次，3次/d。兩組患者連續(xù)治療8周。觀察兩組患者臨床療效，比較治療前后兩組患者典型表現(xiàn)評分，改良Mayo評分和炎癥性腸病問卷（IBDQ）總分，及血清腫瘤壞死因子-α（TNF-α）、白細胞介素-17（IL-17）和單核細胞趨化蛋白-1（MCP-1）水平。結(jié)果 治療后，治療組臨床有效率（94.92%）較對照組（83.05%）顯著增高（P＜0.05）。治療后，兩組腹痛、膿血便及腹瀉評分均顯著低于治療前（P＜0.05），且以治療組的下降更顯著（P＜0.05）。與治療前對比，兩組治療后改良Mayo評分均顯著減少，而IBDQ總分則均顯著增加（P＜0.05），且以治療組2項評分改善更顯著（P＜0.05）。治療后，兩組血清TNF-α、IL-17和MCP-1水平均顯著低于治療前（P＜0.05），且治療后治療組患者血清TNF-α、IL-17和MCP-1水平的降低水平較對照組更顯著（P＜0.05）。結(jié)論 復(fù)方苦參腸炎康片聯(lián)合柳氮磺吡啶對潰瘍性結(jié)腸炎患者具有確切的臨床療效，可有效減輕患者癥狀、促進病情緩解及改善生活質(zhì)量，并能進一步抑制患者體內(nèi)炎癥反應(yīng)，且安全性較好。

Objective To explore the clinical effect of Compound Kushen Changyankang Tablets combined with sulfasalazine in treatment of ulcerative colitis. Methods Patients (118 cases) with ulcerative colitis in Bozhou People's Hospital from March 2019 to July 2021 were randomly divided into control and treatment group, and each group had 59 cases. Patients in the control group were po administered with Sulfasalazine Enteric-coated Tablets, 4 tablets/time, three times daily. Patients in the treatment group were po administered with Compound Kushen Changyankang Tablets on the basis of the control group, 4 tablets/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, the typical performance scores, modified Mayo scores and IBDQ total scores, and the serum levels of TNF-α, IL-17 and MCP-1 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group[94.92% (56/59)] was significantly higher than that of the control group[83.05% (49/59)] (P < 0.05). After treatment, the scores of abdominal pain, purulent and bloody stool and diarrhea in two groups were significantly lower than those before treatment (P < 0.05), especially in the treatment group (P < 0.05). Compared with those before treatment, the modified Mayo score were significantly decreased, while the total score of IBDQ were significantly increased in two groups after treatment (P < 0.05), especially in the treatment group (P < 0.05). After treatment, the levels of serum TNF-α, IL-17 and MCP-1 in two groups were significantly lower than those before treatment (P < 0.05), and the levels of serum TNF-α, IL-17 and MCP-1 in the treatment group were more significantly lower than those in the control group (P < 0.05). Conclusion Compound Kushen Changyankang Tablets combined with sulfasalazine in treatment of ulcerative colitis has definite clinical effect, can effectively reduce the symptoms of patients, promote the remission of the disease and improve the quality of life, and can further inhibit the inflammatory reaction in patients, and it is safe.

R975

亳州市重點研發(fā)計劃項目(bzzc2021023)